Cancer

Patient with IV
Health

Many clinical trials for new cancer drugs didn’t include any data on race

By Megan Thielking

Pharmalot

Pharmalittle: Trump administration pushes for international drug pricing index; is Roche starting a price war in cancer drugs?

By Ed Silverman

Greg Friberg
Biotech

How Amgen plans to BiTE into CAR-T’s hype

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

Roche headquarters
Biotech

Roche drug approval offers a glimpse at the future of cancer treatment

By Matthew Herper

Play
The Readout LOUD

Listen: The serious side of spit kits, how BiTEs leave a mark, & Sarepta’s sluggish study

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

collected blood for CAR-T
First Opinion

Medicare’s ‘new technology’ payment plan doesn’t go far enough

By Roy Silverstein

Saliva collection kit
First Opinion

23andMe had devastating news about my health. I wish a person had delivered it

By Dorothy Pomerantz

CAR-T and cancer cell
Politics

CMS finalizes long-sought rules for Medicare CAR-T coverage

By Nicholas Florko

Pharmalot

Pharmalittle: Pay-to-play clinical trials draw scrutiny; Chinese drug ingredients called U.S. threat

By Elizabeth Cooney

Mammograms
First Opinion

Some people should stop being screened for cancer. Convincing them isn’t always easy

By Nancy L. Schoenborn

Blood tests - vials
Biotech

Blood test could replace biopsy for rare cancer treated by Keytruda

By Matthew Herper

Biotech

Amgen’s KRAS-blocking cancer drug shows broader tumor-killing activity than previously reported

By Adam Feuerstein

F*!@ Disease
Biotech

A mysterious startup launched with an impossibly ambitious rallying cry. Now its plans are coming into focus

By Kate Sheridan

Pharmalot

Pharmalittle: Trump eyes executive order for drug pricing; opioid makers ask judge to toss a key lawsuit

By Ed Silverman

Pfizer Allergan
Health

Allergan recalls textured breast implant tied to rare cancer

By Associated Press

Glioblastoma Cells
In the Lab

A new kind of CAR-T becomes a micro-pharmacy, eliminating glioblastoma in mice

By Sharon Begley

Medical marijuana
First Opinion

I wanted to try medical marijuana. Why couldn’t my doctors help me?

By Shari Berman

Dollars
Biotech

Kronos, a startup led by Gilead alumni, raises $105 million in latest mega-round

By Kate Sheridan

Pancreatic cancer cells
Health Tech

An experimental AI system can predict when pancreatic cysts will become cancerous

By Casey Ross

Pharmalot

Pharmalittle: Pharma keeps winning in Washington; J&J faces test as Oklahoma opioid trial wraps up

By Ed Silverman

Glaxo Smith Kline
Biotech

GSK took a leap of faith on PARP inhibitors in cancer. It may pay off

By Matthew Herper

Pharmalot

Pharmalittle: Glaxo is set to hire a new chairman; Gilead tries to bulk up with new deal

By Ed Silverman

Joe Biden
Politics

Biden Cancer Initiative to suspend operations as 2020 campaign heats up

By Matthew Herper and Lev Facher

Human Melanoma Cell
Biotech

In a small study, a cancer vaccine assist beats immunotherapy drugs alone

By Sharon Begley

Kite Pharma
Biotech

Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit

By Matthew Herper

Play
The Readout LOUD

Listen: A whirlwind week in Washington, Sean Parker’s mansion, & remembering a resonant voice in biotech

By Damian Garde and Rebecca Robbins

Michael Becker
Health

Every data point has a face: What Michael Becker taught us

By Matthew Herper

Parker book
In the Lab

The Parker Institute looks to grow, leveraging outside donors and equity stakes

By Rebecca Robbins

Sean Parker reflection
Heavyweights

Billionaire Sean Parker is nerding out on cancer research. Science has never seen anyone quite like him

By Rebecca Robbins

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy